Oct 29th Day 1

08:29

Opening Plenary Session

Panel discussion
08:40

Paradigm shift in vaccine funding capacity and collaborations for disease X and persistent epidemics

  • How are we incentivizing vaccine development?
  • How will these vaccines reach the LMICs and developing countries?
  • CEPI’s strategy and investment to advance medical countermeasures to emerging diseases
  • The potential of translational medicine and access for all
  • How to secure public funding to advance research and vaccine development
Panel discussion
09:25

Are we pandemic ready for influenza? How to close the gaps in our current strategy in preparedness

  • The importance of cross species consideration in influenza during pre-pandemic preparedness
  • What is our response mechanism in medical and non-medical interventions?
  • European wide actions to provide global health, sustainable policies, coverage and access – joint procurement
  • The role of industry in vaccine matching, manufacturing and antivirals
Laszlo Radvanyi
10:10

What will 2020 hold for immuno-oncology? A global landscape and overview of promising approaches

  • Emerging immuno-oncology targets and modalities
  • Exploring possible uses of artificial intelligence in oncology (patient stratification, predicting patient response to treatment, AI as a diagnostic tool etc)
  • Ensuring patient centricity in oncology clinical trials
  • Looking to the future: How can we go further to make precision medicine a reality for cancer patients?
10:40

Morning Networking Break

2 x Interactive Roundtables

11:40 to 12:25 (rotation one) and 12:25 to 13:10 (rotation two). If you have not filled out the survey please choose them on the sign-up sheets located outside of the exhibition hall/or ask registration for more information. Choose two x 45 min long roundtables for these interactive discussions with like-minded peers in:
11:40

Establishing a One Health approach to combat emerging zoonotic & transboundary diseases

11:40

Further follow up on: Paradigm shift in vaccine funding capacity and collaborations for disease X and persistent epidemics

11:40

Intradermal delivery of therapeutic vaccines – benefits and challenges

11:40

Oncovirus vaccines, status update

11:40

Overcoming current limitations in selecting immunogenic neoantigens

11:40

The development of combination therapies in oncology (biology, regulatory, pathway to approval)

11:40

Virtual trials—do they have a role in vaccine studies

12:25

Are PD-1 Antibodies transforming cancer therapy?

12:25

Biodefence: The role of vaccines in preventing outbreaks, through natural causes or biothreats

12:25

CEPI: CFP2 rolling call

12:25

Eyes wide open- What your sites want to tell you!

12:25

Further follow up on: Are we pandemic ready for influenza? How to close the gaps in our current strategy in preparedness

12:25

Oncolytic Viruses: Only one virus has been approved for routine use, how do we bridge that hurdle?

12:25

Practical use of systems biology in vaccinology

12:25

Strengthening human & animal public health systems at their interface to prevent AMR: Spanish National Action Plan against Antimicrobial Resistance

12:25

Technology transfer: From concept to product

13:10

Networking Lunch & Poster Sessions

14:10

Chair’s opening remarks Influenza Vaccines ​​​​​​​

14:39

Cancer Vaccines

14:39

Influenza Vaccines

14:39

New Platform & Delivery Technologies

14:39

One Health

14:39

Vector Borne Diseases

14:39

What are the AMR targets for vaccines?

Immuno-oncology
14:40

Chair’s opening remarks

AMR
14:40

Chair’s opening remarks

New Technology
14:40

Chair’s opening remarks

Emerging Diseases
14:40

Chair’s opening remarks

New Technology
14:45

The role and potential of platforms: Just a plug and play between inducing immune response or an industrialisation and rapid response tool too?

New Technology
15:30

New adjuvants

Immuno-oncology
15:45

Activating the immune system and exerting anti-cancer activity with an individualized RNA vaccine

Emerging Diseases
16:15

A single-dose live-attenuated Zika vaccine

16:45

Afternoon Networking Break

Immuno-oncology
17:15

Developing personalized neoantigen cancer vaccines to target solid tumors

- Inducing a unique CD8-dominated T cell response- Clinical updates on phase I/IIa VB10.NEO vaccine trial
Emerging Diseases
17:15

New immune-data and correlates analysis on our Ebola vaccine

New Technology
17:15

RNA vaccine advances: Therapeutic & infectious diseases

New Technology
17:30

17:30 Immune profiling and single cell analysis techniques for better vaccine design

Immuno-oncology
17:30

Overcoming current limitations in selecting immunogenic neoantigens- The NeoScreen platform

New Technology
17:45

Structure-based vaccine design

Immuno-oncology
18:00

Investigation of an allogeneic cellular vaccine for treating pancreatic cancer

- Clinical updates on Phase I clinical study to determine the optimal dose for the safe immune restoration and immune response of (ACIT‑1) in adult cancer patients
New Technology
18:00

Rapid development and manufacture of disease X

18:15

Chair closing remarks of day one followed by Drinks Reception

last published: 09/Jul/19 10:05 GMT

Sign Up for Event Updates